Slide 1: Siemens Healthineers AG
Siemens Healthineers AG J.P. Morgan Healthcare Conference, January 13, 2026 1 Unrestricted © Siemens Healthineers, 2025 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This
Slide 3: The innovation powerhouse in global healthcare
Siemens Healthineers The innovation powerhouse in global healthcare Market leader Global reach #1 #1 90% >70 3.0B >700K in Imaging in all of leading hospitals countries with patient installed and Precision regions1 work with us direct presence touchpoints base Therapy >200 360 €6bn €2bn >1,300 13,00
Slide 4: The innovation powerhouse in global healthcare
Siemens Healthineers The innovation powerhouse in global healthcare €23.4bn €3.9bn 16.5% Revenue Adj. EBIT Adj. EBIT margin1 1 The global leader in Imaging FY25 The global leader in oncology 1 Market share2 Revenue split Market share2 38% Imaging €12.1bn >60% CHN Precision Therapy Varian APJ EMEA €6
Slide 5: Elevating Health Globally
Elevating Health Globally — we have uniquely positioned ourselves to tackle the most threatening diseases Neuro- Cardio- vascular Stroke Cancer degenerative Patient Precision Twinning Therapy Healthcare AI 5 Unrestricted © Siemens Healthineers, 2026
Slide 6: Imaging – leading with breakthrough innovations, shaping automated imaging chain
Imaging – leading with breakthrough innovations, and shaping the future of the automated imaging chain Moving whole portfolio to photon-counting Scaling MR DryCool technology across portfolio AI AI- powered 1-click World’s 1st World’s 1st Mid-range 2040: All CTs 0.55T 1.5T 3T PCCT PCCT-Fleet Leadi
Slide 7: Changing clinical pathways with photon-counting CT
Changing clinical pathways with photon-counting CT Screening / early detection Immediate clarity Planning precisely the next step (with CT-guided PCI) Conv. CT UHR PCCT ICA 0.6 mm 0.2 mm Moderate Mild Mild stenosis stenosis stenosis No calcification, no plaque: no risk Reduces need for diagnostic in
Slide 8: Fighting the most threatening diseases with precise therapies
Fighting the most threatening diseases with precise therapies Radiation Oncology Angiography Personalized Image guided Next generation linear accelerators for faster, more precise One unified product platform – AI-powered & procedure focused treatment with improved dose sparing Precision – Seamles
Slide 9: Image-guided, personalized and AI-enabled cancer therapies
Image-guided, personalized and AI-enabled cancer therapies MR-based organs-at-risk contouring Theranostics AI-assisted auto-contouring Pre treatment Treatment response after 92 days Precise planning of radiation therapy PSMA PET confirms tumor Confidently and accurately ensures regression radiosurge
Slide 10: Healthcare AI is a key enabler
Healthcare AI is a key enabler Patient Precision Patient to image Image to report/plan Report/plan to treat Twinning Therapy Healthcare AI 10 Unrestricted © Siemens Healthineers, 2026
Slide 11: Elevating Healthcare AI to the next level
Elevating Healthcare AI to the next level Integrated technology across the system Patient to image Image to report/plan Report/plan to treat From exam companions From radiology findings From auto-contouring to autonomous imaging to radiology report to instant RT planning 11 Unrestricted © Siemens He
Slide 12: We have perfectly positioned ourselves to support customers to overcome their challenges
We have perfectly positioned ourselves to support customers to overcome their challenges Market leader with Global setup for unmatched portfolio local needs Further expand Efficiency Value Partnerships Drive clinical transformation Clinical Excellence through Value Programs Further increase impact A
Slide 13: We integrate workflows from diagnosis to treatment
We integrate workflows from diagnosis to treatment – for faster, simplified procedures and better outcomes Cardiovascular Stroke Neurodegenerative Cancer CT-guided PCI1 @Houston Methodist Stroke treatment @Vall d’Hebron NDD3 care @Link Neuroscience Cancer care @Alberta Seamless integration of CT ins
Slide 14: Reliable revenue, earnings and cash compounder with sound capital deployment
Siemens Healthineers: Reliable revenue, earnings and cash compounder with sound capital deployment Environmental, Social, Reliable Dividend & share buyback Governance revenue Profitable Reliable Balance-sheet strength Shareholder growth free cash Value Organic growth investment Disciplined M&A 14 Un
Slide 15: Outlook 2026
Outlook 2026 FY2025 FY2026E Revenue growth 5.9% Revenue growth 5 to 6% Adj. EPS €2.39 Adj. EPS €2.20 to 2.40 15 Note: Outlook for FY26 is based on several assumptions (see Quarterly Statement Q4 FY25), including year-over-year flattish revenue in China Unrestricted © Siemens Healthineers, 2026
Slide 16: FY2026 is a transition year – defining the baseline for double-digit EPS growth
FY2026 is a transition year – defining the baseline for double-digit EPS growth over the midterm till 2030 Returning to double-digit EPS growth: Transition year FY2026: Operational EPS growth • Underlying operational Mitigating ~€400m tariff impact over the next 3 years: “New Ambition” phase: EPS gr
Slide 17: Mid-term outlook 2027-2030
Mid-term outlook 2027-2030 Imaging Precision Therapy Diagnostics ▪ Mid to high single-digit ▪ High single-digit ▪ Improving towards revenue growth (p.a.) ▪ Margin expansion 6 – 9% revenue growth (p.a.) ▪ Margin expansion by mid single-digit growth ▪ Margin expansion Revenue from scale (p.a.) ~100 bp
Slide 18: Q&A
Q&A 18 Unrestricted © Siemens Healthineers, 2026